feed,title,long_url,short_url
Benzinga,Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease,https://benzinga.com/general/biotech/23/12/36172823/novartis-newly-fda-approved-rare-blood-disorder-drug-aces-phase-3-study-in-ultra-rare-kidney-fail,https://da.gd/ZJv8T4
